Fermion develops, manufactures and markets active pharmaceutical ingredients (APIs) to companies in global generic market as well as under exclusive contracts to companies focusing on new chemical entities (NCEs).
Fermion in brief
Fermion develops, manufactures and markets active pharmaceutical ingredients (APIs) to companies in global generic market as well as under exclusive contracts to companies focusing on new chemical entities (NCEs). Fermion is fully owned subsidiary of Orion Corporation and headquartered in Espoo, Finland. Together with Orion we are a fully integrated contract development and manufacturing organization (CDMO) and offer services covering both drug substances and drug products. All contract manufacturing services of Orion Group are marketed by Fermion.
Our API product portfolio consists of over 30 generic APIs and over 10 NCEs. Fermion’s two state-of-the-art manufacturing sites as well as R&D facilities including a modern bench scale operation are all located in Finland. Fermion has systematically invested and expanded capabilities in the production of highly potent compounds (HPAPIs).
Focus areas of drug product contract manufacturing services include hormonal and non-hormonal semi-solids, liquids, cytotoxic oral solids and packaging services. Also small volume parenterals and non-cytotoxic oral solids can be offered. We have three manufacturing sites and one packaging center for drug products at Orion.
All Fermion and Orion sites operate according to current Good Manufacturing Practice (cGMP) and apply high environmental, health and safety and other sustainability standards. Our facilities are regularly inspected by all the relevant authorities, including the U.S. Food and Drug Administration (FDA), and are frequently audited by our partners and customers.
